G1 Therapeutics, Inc. (GTHX) Can’t Be More Safe. Trades Significantly Higher

April 17, 2018 - By Winifred Garcia

The stock of G1 Therapeutics, Inc. (NASDAQ:GTHX) is a huge mover today! The stock increased 13.25% or $4.81 during the last trading session, reaching $41.1. About 125,604 shares traded. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 5 months positive chart setup for the $1.33 billion company. It was reported on Apr, 17 by Barchart.com. We have $43.16 PT which if reached, will make NASDAQ:GTHX worth $66.50 million more.

Analysts await G1 Therapeutics, Inc. (NASDAQ:GTHX) to report earnings on May, 16. After $-0.60 actual earnings per share reported by G1 Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company has market cap of $1.33 billion. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. It currently has negative earnings. The firm has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca's epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.